A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Running, not enrolling · Phase 1
Conditions studied: Glioblastoma
In brief
A Dose Finding Study of \[177Lu\]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
Key facts
- Study ID
- NCT05109728
- Run by
- Novartis Pharmaceuticals
- People needed
- 65
- Starts
- 2022-05-10
- Expected to finish
- 2027-07-31
- Last updated by the study team
- 2026-07-17
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Col Uni Med Center New York Presby — New York, New York, United States
- University of Pittsburgh — Pittsburgh, Pennsylvania, United States
- MD Anderson Cancer Center Uni of Te — Houston, Texas, United States
- University of Wisconsin School of Medicine and Public Health — Madison, Wisconsin, United States
- Novartis Investigative Site — Bron, France
- Novartis Investigative Site — Marseille, France
- Novartis Investigative Site — Porto, Portugal
- Novartis Investigative Site — Granada, Andalusia, Spain
- Novartis Investigative Site — Barcelona, Spain
- Novartis Investigative Site — Barcelona, Spain
- Novartis Investigative Site — Madrid, Spain
- Novartis Investigative Site — Madrid, Spain
- Novartis Investigative Site — Lausanne, Switzerland
- Novartis Investigative Site — Zurich, Switzerland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.